Geneamed Sp. z o.o. (Poland)

Main Activities: Research and Development in Biotechnology (except Nanobiotechnology)

Secondary Activities: Pharmaceutical Preparation Manufacturing | Medical Equipment and Supplies Manufacturing | Other Miscellaneous Nondurable Goods Merchant Wholesalers | Pharmacies and Drug Stores | Department Stores | Other Miscellaneous Store Retailers | Scientific Research and Development Services | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Full name: Geneamed Sp. z o.o.

Profile Updated: August 26, 2025

GeneaMed is a fusion of ideas, creativity and years of experience in the treatment and diagnosis of blood proliferative disorders. The company develops innovative therapeutics for severe neoplastic diseases. The latest invention of GeneaMed is the use of dendrimer-based nanoparticles in the targeted treatment of a group of chronic B-cells Lymphoproliferative Disorders with the most common Chronic Lymphocytic Leukemia .

Headquarters
Ul. Dr. Stefana Kopcinskiego 16/18/904
Lodz; Lodzkie; Postal Code: 90-232

Contact Details: Purchase the Geneamed Sp. z o.o. report to view the information.

Website: http://www.geneamed.com

Basic Information

Total Employees:

Purchase the Geneamed Sp. z o.o. report to view the information.

Registered Capital:

Purchase the Geneamed Sp. z o.o. report to view the information.

Financial Auditors:

Purchase the Geneamed Sp. z o.o. report to view the information.

Incorporation Date:

September 16, 2015

Key Executives

Purchase this report to view the information.

President

Ownership Details

Purchase this report to view the information.

50.85%

Purchase this report to view the information.

49.15%

Company Performance

Financial values in the chart are available after Geneamed Sp. z o.o. report is purchased.

Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service

Key Financial Highlights

Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.

Operating Profit/Loss (EBIT)

15.52%▲

EBITDA

87.86%▲

Net Profit/Loss for the Period

15.74%▲

Total Assets

-10.76%▼

Total Equity

-11.48%▼

Return on Equity (ROE)

0.66%▲

Quick Ratio

-0.04%▼

Cash Ratio

-0.04%▼

Similar companies